Participant flow

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2019-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   40 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

   id

   FG000

   title

   BT062 40 mg/m²

2. description

   50 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

   id

   FG001

   title

   BT062 50 mg/m²

3. description

   65 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

   id

   FG002

   title

   BT062 65 mg/m²

4. description

   80 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

   id

   FG003

   title

   BT062 80 mg/m²

5. description

   100 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

   id

   FG004

   title

   BT062 100 mg/m²

6. description

   120 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

   id

   FG005

   title

   BT062 120 mg/m²

7. description

   140 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

   id

   FG006

   title

   BT062 140 mg/m²

8. description

   160 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

   id

   FG007

   title

   BT062 160 mg/m²

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         3

      3. group Id

         FG002

         num Subjects

         4

      4. group Id

         FG003

         num Subjects

         3

      5. group Id

         FG004

         num Subjects

         4

      6. group Id

         FG005

         num Subjects

         3

      7. group Id

         FG006

         num Subjects

         10

      8. group Id

         FG007

         num Subjects

         4

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         3

      3. group Id

         FG002

         num Subjects

         4

      4. group Id

         FG003

         num Subjects

         3

      5. group Id

         FG004

         num Subjects

         2

      6. group Id

         FG005

         num Subjects

         3

      7. group Id

         FG006

         num Subjects

         6

      8. group Id

         FG007

         num Subjects

         2

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         2

      6. group Id

         FG005

         num Subjects

         0

      7. group Id

         FG006

         num Subjects

         4

      8. group Id

         FG007

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The Intention-to-treat (ITT) population included all subjects who were enrolled in the study and received at least 1 dose of BT062 and who had any post-Baseline evaluations or data. One subject did not have at least one post-injection assessment of the treatment response and was excluded from both the ITT and PP populations (n = 34).

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice